The immunogenetic link with posttreatment control is rather with ‘disease susceptible’ HLA-I, potentially through reduced immune activation via strong LILR-B2-binding affinities, and with HLA haplotypes that favour KIR education of NK cells and more effective antiviral NK responses in HIV infection. The gene discussed is KIR3DL1; the disease is HIV infectious disease.